Prostate Cancer Update Think Tank 1

SELECT PUBLICATIONS

Albrecht W et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study. Eur Urol 2003;44(5):505-11. Abstract

Bruchovsky N et al. Locally advanced prostate cancer — biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 2007;109(5):858-67. Abstract

Bruchovsky N et al. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: Clinical parameters. Cancer 2006;107(2):389-95. Abstract

D’Amico AV et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95(18):1376-83. Abstract

Freedland SJ et al. Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007;25(13):1765-71. Abstract

Freedland SJ et al. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006;176(4 Pt 1):1404-8. Abstract

Freedland SJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9. Abstract

Hainsworth JD et al. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Clin Genitourin Cancer 2006;4(4):287-92. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Southwest Oncology Group, Berry DL et al. Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006;24(18):2828-35. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Taplin ME et al. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006;24(34):5408-13. Abstract